hsa-mir-326: Hsa-mir-326 is a microRNA that has been studied in the context of cancer, specifically in resistant chronic myeloid leukemia (CML) patients [PMC2743636]. In a study comparing resistant and responder samples, it was found that 18 miRNAs, including hsa-mir-326, were down-regulated in resistant CML patients [PMC2743636]. Only one miRNA, hsa-miR-191, was found to be up-regulated in the resistant samples [PMC2743636]. The overexpression of hsa-mir-326 has been shown to have beneficial effects in animal models of non-small cell lung cancer (NSCLC), including decreased tumor growth, metastasis, and PD-L1 expression [PMC9659572]. Additionally, it was found to increase the infiltration of CD8+ cells and TNF-α+ IFN-γ+ CD8+ T-cells population in tumor tissues [PMC9659572]. In another analysis comparing responder and nonresponder samples, it was observed that responder samples had significantly elevated expression of hsa-mir-326 compared to nonresponder samples [PMC7794682]. These findings suggest that hsa-mir-326 may play a role in cancer resistance and response to treatment. Further research is needed to fully understand its mechanisms and potential therapeutic applications.